On February 2, 2026, Medtronic announced three new developments for the company’s 780G automated insulin-delivery (AID) system — cleared for use last year by the US FDA in type 2 diabetes (T2D) — ...
With CE Mark approval, the benefits of the MiniMed™ 780G system are now available with a new sensor that takes less than 10 seconds to insert1 DUBLIN, Jan. 8, 2024 /PRNewswire/ -- Medtronic plc ...
Medtronic plc MDT recently achieved the CE Mark for the MiniMed 780G system with Simplera Sync, a disposable, all-in-one continuous glucose monitor (CGM) that does not require any fingersticks or over ...
The US Food and Drug Administration (FDA) has granted approval for the use of Medtronic’s disposable Simplera Sync sensor with the MiniMed 780G system. The all-in-one sensor is said to eliminate the ...
Medtronic has commercially launched its MiniMed 780G system in the US, now integrated with Abbott’s Instinct sensor. The Instinct sensor utilises Abbott’s continuous glucose monitoring (CGM) ...
TOLOCHENAZ, SWITZERLAND - Medtronic, Inc. today announced the European launch of MiniMed® Duo(TM), the world's first two-in-one breakthrough that combines a glucose sensor and insulin infusion set ...
Medtronic said it plans to begin making the combined package available in Europe, for people with diabetes aged 7 and up, through a limited release starting spring 2024. (Medtronic) Medtronic has ...
Real-time actionable insights on one mobile app for people who manage their diabetes using multiple daily injections GALWAY, Ireland, Feb. 25, 2026 /PRNewswire/ -- Medtronic (NYSE: MDT), a global ...
DUBLIN, Jan. 8, 2024 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced CE (Conformité Européenne) Mark approval for the MiniMed™ 780G system with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results